Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Acute Coronary Syndrome

ClinicalTrials.gov lists 1,456 trials for Acute Coronary Syndrome or a narrower condition beneath it. AstraZeneca has the most among industry and government lead sponsors, with 33.

MeSH D054058 Cardiovascular Diseases C14
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 35 Phase 1/2 Phase 1/2 12 Phase 2 Phase 2 64 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 115 Phase 4 Phase 4 227 Not applicable Not applicable 410 Observational Observational 582 Phase 1 Phase 1 35 Phase 1/2 Phase 1/2 12 Phase 2 Phase 2 64 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 115 Phase 4 Phase 4 227 Not applicable Not applicable 410 Observational Observational 582

Trials per phase (log scale)

1,456 of the 1,456 trials are tagged with Acute Coronary Syndrome itself; the rest are tagged with a narrower condition beneath it.

Get the Acute Coronary Syndrome report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Acute Coronary Syndrome trials start? (30)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 88

1995: 1 trials (Observational 1) 1997: 1 trials (Observational 1) 1999: 1 trials (Phase 3 1) 2000: 1 trials (Observational 1) 2001: 3 trials (Observational 1, Not applicable 1, Phase 3 1) 2002: 5 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 1) 2003: 12 trials (Observational 3, Phase 4 2, Phase 3 6, Phase 2 1) 2004: 10 trials (Observational 1, Not applicable 1, Phase 4 4, Phase 3 3, Phase 2/3 1) 2005: 20 trials (Observational 7, Not applicable 3, Phase 4 1, Phase 3 5, Phase 2 3, Phase 1 1) 2006: 43 trials (Observational 15, Not applicable 10, Phase 4 6, Phase 3 7, Phase 2 4, Phase 1 1) 2007: 37 trials (Observational 13, Not applicable 5, Phase 4 6, Phase 3 5, Phase 2 6, Phase 1/2 1, Phase 1 1) 2008: 39 trials (Observational 12, Not applicable 10, Phase 4 6, Phase 3 5, Phase 2/3 1, Phase 2 4, Phase 1/2 1) 2009: 50 trials (Observational 15, Not applicable 11, Phase 4 11, Phase 3 7, Phase 2 5, Phase 1 1) 2010: 77 trials (Observational 28, Not applicable 18, Phase 4 13, Phase 3 11, Phase 2/3 1, Phase 2 2, Phase 1/2 3, Phase 1 1) 2011: 64 trials (Observational 29, Not applicable 13, Phase 4 8, Phase 3 9, Phase 2 3, Phase 1 2) 2012: 69 trials (Observational 18, Not applicable 17, Phase 4 22, Phase 3 5, Phase 2 3, Phase 1 4) 2013: 73 trials (Observational 28, Not applicable 18, Phase 4 15, Phase 3 7, Phase 2 2, Phase 1 3) 2014: 78 trials (Observational 30, Not applicable 20, Phase 4 18, Phase 3 4, Phase 2/3 1, Phase 2 1, Phase 1 4) 2015: 79 trials (Observational 33, Not applicable 24, Phase 4 14, Phase 3 2, Phase 2 3, Phase 1/2 2, Phase 1 1) 2016: 77 trials (Observational 28, Not applicable 25, Phase 4 15, Phase 3 3, Phase 2/3 2, Phase 2 2, Phase 1/2 1, Phase 1 1) 2017: 71 trials (Observational 38, Not applicable 20, Phase 4 7, Phase 3 2, Phase 2 1, Phase 1/2 1, Phase 1 2) 2018: 76 trials (Observational 44, Not applicable 15, Phase 4 9, Phase 3 5, Phase 2 2, Phase 1 1) 2019: 76 trials (Observational 39, Not applicable 24, Phase 4 8, Phase 3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2020: 56 trials (Observational 24, Not applicable 17, Phase 4 7, Phase 3 2, Phase 2 4, Phase 1/2 1, Phase 1 1) 2021: 88 trials (Observational 36, Not applicable 23, Phase 4 16, Phase 3 3, Phase 2/3 3, Phase 2 4, Phase 1 3) 2022: 69 trials (Observational 29, Not applicable 25, Phase 4 7, Phase 3 2, Phase 2 5, Phase 1 1) 2023: 62 trials (Observational 23, Not applicable 23, Phase 4 6, Phase 3 8, Phase 2 2) 2024: 73 trials (Observational 34, Not applicable 24, Phase 4 6, Phase 3 2, Phase 2/3 2, Phase 2 3, Phase 1/2 1, Phase 1 1) 2025: 65 trials (Observational 24, Not applicable 29, Phase 4 5, Phase 3 2, Phase 2 2, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 74
2025 65
2024 73
2023 62
2022 69
2021 88
2020 56
2019 76
2018 76
2017 71

Showing 10 of 30 earlier years.

Start your 14-day trial Email me all 30 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 92 trials starting in 2026 and about 77 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 111 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 892 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Acute Coronary Syndrome trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 35
Phase 1/2 12
Phase 2 64
Phase 2/3 11
Phase 3 115
Phase 4 227
Not applicable 410
Observational 582

How many Acute Coronary Syndrome trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 74
Recruiting 154
Enrolling by invitation 4
Active, not recruiting 42
Completed 766

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Acute Coronary Syndrome trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
AstraZeneca 33
GlaxoSmithKline 10

Which drugs are being tested for Acute Coronary Syndrome? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
ATORVASTATIN 20
ROSUVASTATIN 19
Rivaroxaban 16
LOVENOX 10
Cangrelor 9

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Clopidogrel 75 78
Ticagrelor (Brilique) 90 73
Prasugel 42
EC Aspirin 29
Colchicines 13

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Acute Coronary Syndrome trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Angina unstable 2,876 27
Pneumonia 2,393 36
Non-cardiac chest pain 2,145 23
Angina pectoris 2,068 23
Other hospitalizations 1,857 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Acute Coronary Syndrome? (2,005)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
A Remote Nursing-Guided Secondary Prevention Programme in Acute Coronary Syndrome. The SPRING Randomised Controlled Trial. Journal of advanced nursing 2026 Yes
Clinical Performance of a Novel Point-of-Care High-Sensitivity Cardiac Troponin I Assay. The journal of applied laboratory medicine 2026 Yes
Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempedACS Randomized Clinical Trial. Circulation 2026 Yes
Potent P2Y<sub>12</sub> Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy. Journal of the American College of Cardiology 2026 Yes
Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome. Circulation 2026 Yes

Showing 5 of 2,005 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages